For the Media
Dr. Stanley Riddell is a member of Fred Hutch's Clinical Research Division and a co-founder of the Program in Immunology. Dr. Riddell led the first human trial of adoptively transferred T cell clones to prevent cytomegalovirus infection after allogeneic hematopeietic transplantation. His research team has developed new techniques for isolation, expansion, genetic modification and reinfusion of T cells, and for monitoring safety, persistence, migration and function after transfer. Many of these innovative methods are now widely used.
For the past several years, the Riddell lab has worked on defining the principles of successful adoptive T cell therapy with genetically modified T cells to treat human malignancies.
Below are selected recent articles on adoptive T-cell transfer and CAR T cells. For a more complete list of publications, click here.
The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunology Research 3: 125-135, 2015; Hudecek M, Sommermeyer D, Kosasih PL Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR.
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunology Research 2: 206-216, 2015; Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A. Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR.
Design and implementation of adoptive T cell therapy with chimeric antigen receptor modified T cells. Immunological Reviews 257:127-44, 2014; Jensen MC, Riddell SR.
Serial transfer of single cell-derived immunocompetence reveals stemness of CD8+ central memory T cells. Immunity, 41:116-126, 2014; Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, Drexler I, Höfer T, Riddell SR, Busch DH.
TCR-ligand koff-rates identify antigen-specific CD8+ T cells with superior protective capacity for adoptive transfer. Science Translational Medicine, 5:192ra87, 2013; Nauerth M, Weisbruch B, Knall R, Franz T, Dossinger G, Bet J, Paszkiewicz PJ, Pfeiffer L, Uckert W, Holtappels R, Reddehase MJ, Riddell SR, Busch DH.
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells Blood 119: 72-82, 2012; Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.